Quality of Life Improvements Following Eltrombopag
Treatment in Children with Chronic Immune
Thrombocytopenia: Case Report
Nongnuch Sirachainan MD¹, Pakawan Wongwerawattanakoon BSc², Duantida Songdej MD, PhD¹,
Ampaiwan Chuansumrit MD¹, Surapong Lertthammakiat MD¹ , ³
Affiliation :
¹ Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand ² Department of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand ³ Chakri Naruebodindr Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
The present case series described six chronic immune thrombocytopenia patients (cITP), with a median age of 7.7 (7.0 to 13.0) years and low
platelet count at 15,500 (7,000 to 20,000)/uL. They were suffering from bleeding symptoms and side effects of treatment. After enrollment, they
were treated with thrombopoietin receptor agonist (eltrombopag). Five patients responded positively, showing a median platelet count of 115,000
(39,000 to 433,000)/uL. The median dose of eltrombopag used was 1.3 (0.8 to 2.2) mg/kg/day. The quality of life (QoL) improved for all patients,
with their median overall score using a Pediatric QoL questionnaire showing 25.0% improvement. Median scores also showed improvements
in each sphere of life functioning as physical (30.8%), emotional (26.4%), social (16.4%), and school (21.4%). The present report demonstrated
that a select group of cITP patients, with low platelet count and bleeding symptoms, benefitted from treatment with eltrombopag, as shown by
increased platelet counts and improved QoL.
Received 2 November 2020 | Revised 2 February 2021 | Accepted 3 February 2021
doi.org/10.35755/jmedassocthai.2021.04.11651
Keywords :
Chronic ITP, Thrombopoietin receptor agonist, Children
All Articles
Download